



**Australian Government**  
**Department of Health**

**Ministerial Submission – Standard  
MS19-000434 Version (1)  
Date sent to MO: 01/03/19**

**To: Minister Hunt**

**Subject: MEDICAL DEVICE CONSULTATIONS – THIRD PACKAGE**

**Critical date: 18 March 2019** to enable public consultations to be conducted until 29 April 2019.

s 22

THIS DOCUMENT HAS BEEN RELEASED UNDER  
THE FREEDOM OF INFORMATION ACT 1982  
BY THE DEPARTMENT OF HEALTH

THIS DOCUMENT HAS BEEN RELEASED UNDER  
THE FREEDOM OF INFORMATION ACT 1982  
BY THE DEPARTMENT OF HEALTH

THIS DOCUMENT HAS BEEN RELEASED UNDER  
THE FREEDOM OF INFORMATION ACT 1982  
BY THE DEPARTMENT OF HEALTH

The consultation paper at Attachment E **proposes to introduce a new classification rule for substances introduced into the body via body orifice or applied to the skin.** This includes examples such as weight loss capsules that expand in the stomach; vaginal gels that maintain pH balance or treat bacterial vaginosis; salivation stimulation lozenges, throat lozenges and saline nasal solution sprays. It is proposed that these devices will be reclassified from low-risk/low-medium risk (Class I/Class IIa) to low-medium/medium/high risk (Class IIa/Class IIb/Class III) depending on the location in the body and where the device achieves its intended purpose.

THIS DOCUMENT HAS BEEN RELEASED UNDER  
THE FREEDOM OF INFORMATION ACT 1982  
BY THE DEPARTMENT OF HEALTH